This study is for adults aged 18 to 74 with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. It aims to see if different doses of a medicine called BI 3000202 can help manage SLE symptoms. You would be randomly assigned to one of five groups: four groups receive different doses of BI 3000202, and one group receives a placebo (a pill with no medicine). All participants continue their usual SLE treatment. The study will measure if participants achieve a specific improvement in their SLE symptoms by Week 32. The study is currently enrolling about 405 participants.

Study design

This is an interventional study where participants are randomly assigned to one of five groups. Four groups receive different doses of BI 3000202, and one group receives a placebo.

What's involved

You would take tablets for one year and continue your regular SLE treatment. You would visit the study site regularly for a bit longer than one year for health checks and to note any side effects.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at Week 32, but participants are in the study for a bit longer than one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.